Familial adenomatous polyposis: Translating molecular advances into clinical practice

Research output: Contribution to journalArticle

Abstract

The rapid case of cancer gene discovery has opened a new avenue for cancer risk assessment and predictive gene testing. Familial adenomatous polyposis (FAP) has provided a model for translating research into clinical practice at multiple levels: mutation analysis, molecular testing methods, genetic counselling, and preventive intervention. FAP, an autosomal dominant syndrome of multiple adenomatous polyps in the colon and upper gastrointestinal tract, carries a significantly increased risk of colon cancer and other tumours. Since the discovery of APC as the causal gene, FAP is now recognised as one of the few cancer syndromes for which gene tests are clinically used. APC gene testing, accompanied by genetic counselling, is useful for confirming the diagnosis of FAP, and for testing at-risk individuals: those who test negative for APC mutations can be spared the conventional intensive colon screening regimen and the worry of cancer risk and prophylactic surgery. Eventually, non-surgical interventions may be possible for APC gene mutation carriers.

Original languageEnglish (US)
Pages (from-to)7-10
Number of pages4
JournalCancer Forum
Volume21
Issue number1
StatePublished - 1997
Externally publishedYes

Fingerprint

Adenomatous Polyposis Coli
APC Genes
Genetic Counseling
Mutation
Neoplasms
Colon
Genes
Adenomatous Polyps
Upper Gastrointestinal Tract
Neoplasm Genes
Genetic Association Studies
Colonic Neoplasms
Research

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Familial adenomatous polyposis : Translating molecular advances into clinical practice. / Petersen, Gloria M; Gruber, S.

In: Cancer Forum, Vol. 21, No. 1, 1997, p. 7-10.

Research output: Contribution to journalArticle

@article{ea12c1279c2b4a958350cc1e62433575,
title = "Familial adenomatous polyposis: Translating molecular advances into clinical practice",
abstract = "The rapid case of cancer gene discovery has opened a new avenue for cancer risk assessment and predictive gene testing. Familial adenomatous polyposis (FAP) has provided a model for translating research into clinical practice at multiple levels: mutation analysis, molecular testing methods, genetic counselling, and preventive intervention. FAP, an autosomal dominant syndrome of multiple adenomatous polyps in the colon and upper gastrointestinal tract, carries a significantly increased risk of colon cancer and other tumours. Since the discovery of APC as the causal gene, FAP is now recognised as one of the few cancer syndromes for which gene tests are clinically used. APC gene testing, accompanied by genetic counselling, is useful for confirming the diagnosis of FAP, and for testing at-risk individuals: those who test negative for APC mutations can be spared the conventional intensive colon screening regimen and the worry of cancer risk and prophylactic surgery. Eventually, non-surgical interventions may be possible for APC gene mutation carriers.",
author = "Petersen, {Gloria M} and S. Gruber",
year = "1997",
language = "English (US)",
volume = "21",
pages = "7--10",
journal = "Cancer Forum",
issn = "0311-306X",
publisher = "The Cancer Council Australia",
number = "1",

}

TY - JOUR

T1 - Familial adenomatous polyposis

T2 - Translating molecular advances into clinical practice

AU - Petersen, Gloria M

AU - Gruber, S.

PY - 1997

Y1 - 1997

N2 - The rapid case of cancer gene discovery has opened a new avenue for cancer risk assessment and predictive gene testing. Familial adenomatous polyposis (FAP) has provided a model for translating research into clinical practice at multiple levels: mutation analysis, molecular testing methods, genetic counselling, and preventive intervention. FAP, an autosomal dominant syndrome of multiple adenomatous polyps in the colon and upper gastrointestinal tract, carries a significantly increased risk of colon cancer and other tumours. Since the discovery of APC as the causal gene, FAP is now recognised as one of the few cancer syndromes for which gene tests are clinically used. APC gene testing, accompanied by genetic counselling, is useful for confirming the diagnosis of FAP, and for testing at-risk individuals: those who test negative for APC mutations can be spared the conventional intensive colon screening regimen and the worry of cancer risk and prophylactic surgery. Eventually, non-surgical interventions may be possible for APC gene mutation carriers.

AB - The rapid case of cancer gene discovery has opened a new avenue for cancer risk assessment and predictive gene testing. Familial adenomatous polyposis (FAP) has provided a model for translating research into clinical practice at multiple levels: mutation analysis, molecular testing methods, genetic counselling, and preventive intervention. FAP, an autosomal dominant syndrome of multiple adenomatous polyps in the colon and upper gastrointestinal tract, carries a significantly increased risk of colon cancer and other tumours. Since the discovery of APC as the causal gene, FAP is now recognised as one of the few cancer syndromes for which gene tests are clinically used. APC gene testing, accompanied by genetic counselling, is useful for confirming the diagnosis of FAP, and for testing at-risk individuals: those who test negative for APC mutations can be spared the conventional intensive colon screening regimen and the worry of cancer risk and prophylactic surgery. Eventually, non-surgical interventions may be possible for APC gene mutation carriers.

UR - http://www.scopus.com/inward/record.url?scp=0030760443&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030760443&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0030760443

VL - 21

SP - 7

EP - 10

JO - Cancer Forum

JF - Cancer Forum

SN - 0311-306X

IS - 1

ER -